<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31999745</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A novel gamma radiation-inactivated sabin-based polio vaccine.</ArticleTitle><Pagination><StartPage>e0228006</StartPage><MedlinePgn>e0228006</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0228006</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0228006</ELocationID><Abstract><AbstractText>A concerted action on the part of international agencies and national governments has resulted in the near-eradication of poliomyelitis. However, both the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV) have deficiencies which make them suboptimal for use after global eradication. OPV is composed of attenuated Sabin strains and stimulates robust immunity, but may revert to neurovirulent forms in the intestine which can be shed and infect susceptible contacts. The majority of IPV products are manufactured using pathogenic strains inactivated with formalin. Upon eradication, the production of large quantities of pathogenic virus will present an increased biosecurity hazard. A logical ideal endgame vaccine would be an inactivated form of an attenuated strain that could afford protective immunity while safely producing larger numbers of doses per unit of virus stock than current vaccines. We report here the development of an ionizing radiation (IR)-inactivated Sabin-based vaccine using a reconstituted Mn-decapeptide (MDP) antioxidant complex derived from the radioresistant bacterium Deinococcus radiodurans. In bacteria, Mn2+-peptide antioxidants protect proteins from oxidative damage caused by extreme radiation exposure. Here we show for the first time, that MDP can protect immunogenic neutralizing epitopes in picornaviruses. MDP protects epitopes in Polio Virus 1 and 2 Sabin strains (PV1-S and PV2-S, respectively), but viral genomic RNA is not protected during supralethal irradiation. IR-inactivated Sabin viruses stimulated equivalent or improved neutralizing antibody responses in Wistar rats compared to the commercially used IPV products. Our approach reduces the biosecurity risk of the current PV vaccine production method by utilizing the Sabin strains instead of the wild type neurovirulent strains. Additionally, the IR-inactivation approach could provide a simpler, faster and less costly process for producing a more immunogenic IPV. Gamma-irradiation is a well-known method of virus inactivation and this vaccine approach could be adapted to any pathogen of interest.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tobin</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Biological Mimetics, Inc., Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobin</LastName><ForeName>John K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Biological Mimetics, Inc., Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaidamakova</LastName><ForeName>Elena K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiggins</LastName><ForeName>Taralyn J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Biological Mimetics, Inc., Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bushnell</LastName><ForeName>Ruth V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Biological Mimetics, Inc., Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wai-Ming</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Biological Mimetics, Inc., Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matrosova</LastName><ForeName>Vera Y</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dollery</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-1712-3811</Identifier><AffiliationInfo><Affiliation>Biological Mimetics, Inc., Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeks</LastName><ForeName>Heather N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Defense Threat Reduction Agency, Ft. Belvoir, VA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kouiavskaia</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumakov</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R43 AI120260</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005720" MajorTopicYN="Y">Gamma Rays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Two co-authors are employed by the Department of Defense. MJD is a Professor at the Uniformed Services University Health Sciences. Dr. Daly participated in all aspects of the project but he and his University have no control over funding. HNM is a Program Officer at one of the two funding agencies, DTRA. Dr. Meeks played a role in the conceptualization of the overarching research aims, in the analysis and interpretation of the data, and in manuscript editing. Dr. Meeks has no role in decisions regarding funding these types of applications that are submitted to DTRA. The two funding agencies provided support in the form of salaries for all authors with the exception of MJD who is a fully-funded Professor at USUHS and HNM who is a fully-funded employee at DTRA. The specific roles of these authors are articulated in the &#x2018;author contributions&#x2019; section. The commercial nature of Biological Mimetics, Inc. does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31999745</ArticleId><ArticleId IdType="pmc">PMC6991977</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0228006</ArticleId><ArticleId IdType="pii">PONE-D-19-18205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garon JR, Cochi SL, Orenstein WA. The Challenge of Global Poliomyelitis Eradication. Infect Dis Clin North Am. 2015;29(4):651&#x2013;65. Epub 2015/11/28. 10.1016/j.idc.2015.07.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2015.07.003</ArticleId><ArticleId IdType="pmc">PMC10544864</ArticleId><ArticleId IdType="pubmed">26610419</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14(5):749&#x2013;62. Epub 2015/01/20. 10.1586/14760584.2015.1001750 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.1001750</ArticleId><ArticleId IdType="pubmed">25597843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopalco PL. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect. 2017;145(3):413&#x2013;9. Epub 2016/11/22. 10.1017/S0950268816002569 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816002569</ArticleId><ArticleId IdType="pmc">PMC9507676</ArticleId><ArticleId IdType="pubmed">27866483</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication. Methods Mol Biol. 2016;1387:1&#x2013;10. Epub 2016/03/18. 10.1007/978-1-4939-3292-4_1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3292-4_1</ArticleId><ArticleId IdType="pubmed">26983727</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev Biol (Basel). 2001;105:75&#x2013;80. Epub 2002/01/05. .</Citation><ArticleIdList><ArticleId IdType="pubmed">11763340</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Dunn G, Ramsay ME, Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol. 2005;75(1):153&#x2013;60. Epub 2004/11/16. 10.1002/jmv.20250 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20250</ArticleId><ArticleId IdType="pubmed">15543587</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693&#x2013;708. Epub 2016/01/12. 10.1586/14760584.2016.1140041 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1140041</ArticleId><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>Two out of three wild poliovirus strains eradicated WHO website: World Health Organization; 2019 [cited 2019 10/29/2019]. Available from: https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated.</Citation></Reference><Reference><Citation>Global Polio Iradication Initiative. Polio Eradication &amp; EndgameStrategic Plan 2013&#x2013;2018. 2013.</Citation></Reference><Reference><Citation>Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210 Suppl 1:S459&#x2013;64. Epub 2014/10/16. 10.1093/infdis/jiu128 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu128</ArticleId><ArticleId IdType="pubmed">25316868</ArticleId></ArticleIdList></Reference><Reference><Citation>Salk JE, Gori JB. A review of theoretical, experimental, and practical considerations in the use of formaldehyde for the inactivation of poliovirus. Ann N Y Acad Sci. 1960;83:609&#x2013;37. Epub 1960/01/13. 10.1111/j.1749-6632.1960.tb40933.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1960.tb40933.x</ArticleId><ArticleId IdType="pubmed">14441021</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver SC, Pfeffer M, Marriott K, Kang W, Kinney RM. Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks. Am J Trop Med Hyg. 1999;60(3):441&#x2013;8. Epub 1999/08/31. 10.4269/ajtmh.1999.60.441 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.1999.60.441</ArticleId><ArticleId IdType="pubmed">10466974</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol. 1995;142(2):109&#x2013;40; discussion 7&#x2013;8. Epub 1995/07/15. 10.1093/oxfordjournals.aje.a117611 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a117611</ArticleId><ArticleId IdType="pubmed">7598112</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand. 1993;81:103&#x2013;7. Epub 1993/01/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">8174792</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. WHO Expert Committee on Biological Standardization. Sixty-fifth report (Annex 3). World Health Organ Tech Rep Ser. 2015;(993):1&#x2013;262. Epub 2015/12/31. .</Citation><ArticleIdList><ArticleId IdType="pubmed">26714369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis I, Ottosen A, Rubin J, Blanc DC, Zipursky S, Wootton E. A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market. J Infect Dis. 2017;216(suppl_1):S33&#x2013;s9. Epub 2017/08/26. 10.1093/infdis/jiw550</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw550</ArticleId><ArticleId IdType="pmc">PMC5853471</ArticleId><ArticleId IdType="pubmed">28838159</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Affordable IPV: Developing affordable inactivated polio vaccine. 2019. Available from: http://polioeradication.org/tools-and-library/current-research-areas/affordable-ipv/.</Citation></Reference><Reference><Citation>Kersten G, Hazendonk T, Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine. 1999;17(15&#x2013;16):2059&#x2013;66. Epub 1999/04/27. 10.1016/s0264-410x(98)00409-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0264-410x(98)00409-5</ArticleId><ArticleId IdType="pubmed">10217607</ArticleId></ArticleIdList></Reference><Reference><Citation>Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine. 2007;25(41):7041&#x2013;6. Epub 2007/09/11. 10.1016/j.vaccine.2007.07.060 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.07.060</ArticleId><ArticleId IdType="pubmed">17825459</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaidamakova EK, Myles IA, McDaniel DP, Fowler CJ, Valdez PA, Naik S, et al. Preserving immunogenicity of lethally irradiated viral and bacterial vaccine epitopes using a radio- protective Mn2+-Peptide complex from Deinococcus. Cell Host Microbe. 2012;12(1):117&#x2013;24. Epub 2012/07/24. 10.1016/j.chom.2012.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2012.05.011</ArticleId><ArticleId IdType="pmc">PMC4073300</ArticleId><ArticleId IdType="pubmed">22817993</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly MJ, Gaidamakova EK, Matrosova VY, Kiang JG, Fukumoto R, Lee DY, et al. Small-molecule antioxidant proteome-shields in Deinococcus radiodurans. PloS ONE. 2010;5(9):e12570 Epub 2010/09/15. 10.1371/journal.pone.0012570</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012570</ArticleId><ArticleId IdType="pmc">PMC2933237</ArticleId><ArticleId IdType="pubmed">20838443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayen M, Gupta P, Morazzani EM, Gaidamakova EK, Knollmann-Ritschel B, Daly MJ, et al. Deinococcus Mn(2+)-peptide complex: A novel approach to alphavirus vaccine development. Vaccine. 2017;35(29):3672&#x2013;81. Epub 2017/06/04. 10.1016/j.vaccine.2017.05.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.05.016</ArticleId><ArticleId IdType="pubmed">28576570</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya Y. Return of inactivated whole-virus vaccine for superior efficacy. &#x200e;Immunol. Cell Biol. 2012;90(6):571&#x2013;8. Epub 2011/08/17. 10.1038/icb.2011.70 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2011.70</ArticleId><ArticleId IdType="pubmed">21844883</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Food Irradiation. Available at: http://wwwfdagov/Food/ResourcesForYou/Consumers/ucm261680htm. 2016.</Citation></Reference><Reference><Citation>Seo HS. Application of radiation technology in vaccines development. Clin Exp Vaccine Res. 2015;4(2):145&#x2013;58. Epub 2015/07/29. 10.7774/cevr.2015.4.2.145 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2015.4.2.145</ArticleId><ArticleId IdType="pmc">PMC4524899</ArticleId><ArticleId IdType="pubmed">26273573</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly MJ. A new perspective on radiation resistance based on Deinococcus radiodurans. Nat Rev Microbiol. 2009;7(3):237&#x2013;45. Epub 2009/01/28. 10.1038/nrmicro2073 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2073</ArticleId><ArticleId IdType="pubmed">19172147</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert RD, Hawes IA, Ramachandran PS, Ramesh A, Crawford ED, Pak JE, et al. Pan-viral serology implicates enteroviruses in acute flaccid myelitis. Nat Med. 2019. 10.1038/s41591-019-0613-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0613-1</ArticleId><ArticleId IdType="pmc">PMC6858576</ArticleId><ArticleId IdType="pubmed">31636453</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xe4;rber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Pathol u Pharmakol. 1931;162(4):480&#x2013;3.</Citation></Reference><Reference><Citation>Spearman C. The Method of Right and Wrong Cases ('Constant Stimuli') Without Gauss's Formulae. Br J Psychol. 1908;2:227&#x2013;42.</Citation></Reference><Reference><Citation>Kangro H, Mahy B. Virology Methods Manual 1st ed, Academic Press, 1996.</Citation></Reference><Reference><Citation>Rezapkin G, Dragunsky E, Chumakov K. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV). Biologicals. 2005;33(1):17&#x2013;27. Epub 2005/02/17. 10.1016/j.biologicals.2004.11.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2004.11.003</ArticleId><ArticleId IdType="pubmed">15713553</ArticleId></ArticleIdList></Reference><Reference><Citation>Bockstal V, Sanders B, Achterberg R, Tiemessen M, Bogaert L, Van der Meer M, et al. A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing. Vaccine. 2018;36(21):2917&#x2013;20. Epub 2018/04/25. 10.1016/j.vaccine.2018.04.024 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.04.024</ArticleId><ArticleId IdType="pubmed">29685598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WM, Chen Y, Wang W, Mosser A. Growth of human rhinovirus in H1-HeLa cell suspension culture and purification of virions. Methods Mol Biol. 2015;1221:49&#x2013;61. Epub 2014/09/28. 10.1007/978-1-4939-1571-2_5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-1571-2_5</ArticleId><ArticleId IdType="pubmed">25261306</ArticleId></ArticleIdList></Reference><Reference><Citation>Swift GH, Peyton MJ, MacDonald RJ. Assessment of RNA quality by semi-quantitative RT-PCR of multiple regions of a long ubiquitous mRNA. BioTechniques. 2000;28(3):524, 6, 8, 30&#x2013;1. Epub 2000/03/21. 10.2144/00283rr01 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/00283rr01</ArticleId><ArticleId IdType="pubmed">10723567</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steenis G, van Wezel AL, Sekhuis VM. Potency testing of killed polio vaccine in rats. Dev Biol Stand. 1981;47:119&#x2013;28. Epub 1981/01/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">6262142</ArticleId></ArticleIdList></Reference><Reference><Citation>Peana M, Medici S, Pangburn HA, Lamkin TJ, Ostrowska M, Gumienna-Kontecka E, et al. Manganese binding to antioxidant peptides involved in extreme radiation resistance in Deinococcus radiodurans. J Inorg Biochem. 2016;164:49&#x2013;58. Epub 2016/09/18. 10.1016/j.jinorgbio.2016.08.012 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinorgbio.2016.08.012</ArticleId><ArticleId IdType="pubmed">27637368</ArticleId></ArticleIdList></Reference><Reference><Citation>Duizer E, Rutjes S, de Roda Husman AM, Schijven J. Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014. Euro Surveill. 2016;21(11):30169 Epub 2016/03/30. 10.2807/1560-7917.Es.2016.21.11.30169 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.Es.2016.21.11.30169</ArticleId><ArticleId IdType="pubmed">27020766</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidor E, Plotkin S. Vaccines 6th ed: Saunders; 2012 2012.</Citation></Reference><Reference><Citation>Rezapkin G, Martin J, Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals. 2005;33(1):29&#x2013;39. Epub 2005/02/17. 10.1016/j.biologicals.2004.11.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2004.11.001</ArticleId><ArticleId IdType="pubmed">15713554</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. Food Irradiation: What You Need to Know: 2016. Available from: https://www.fda.gov/food/buy-store-serve-safe-food/food-irradiation-what-you-need-know.</Citation></Reference><Reference><Citation>Peetermans J. Factors affecting the stability of viral vaccines. Dev Biol Stand. 1996;87:97&#x2013;101. Epub 1996/01/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">8854006</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, et al. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine. 2010;28(4):1031&#x2013;40. Epub 2009/11/17. 10.1016/j.vaccine.2009.10.126</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.10.126</ArticleId><ArticleId IdType="pmc">PMC2815090</ArticleId><ArticleId IdType="pubmed">19914193</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>